

REMARKS

Applicants respectfully request that the foregoing amendments be made prior to examination of the present application. The amendments are made to correct multiple dependencies and do not change the scope of the invention.

Respectfully submitted,

Date December 26, 2001

FOLEY & LARDNER
Customer Number: 22428




22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5407

Facsimile: (202) 672-5399

By

 (28,665)



Michele M. Simkin
Attorney for Applicants
Registration No. 34,717

MARKED UP VERSION OF AMENDED CLAIMS

3. (Once Amended) A polypeptide according to claim 1 [or 2] wherein said mutation is at least one deletion.

5. (Once Amended) A polynucleotide encoding a polypeptide according to [any one of claims 1 to 4] claim 1.

9. (Once Amended) A pharmaceutical composition comprising a polypeptide according to claim 1, [any one of claims 1 to 4, a polynucleotide according to claim 5 or a vector according to claim 6] together with a pharmaceutically acceptable carrier [to] or diluent.

10. (Once Amended) A vaccine composition comprising a polypeptide according to claim 1, [any one of claims 1 to 4, a polynucleotide according to claim 5 or a vector according to claim 6] together with a pharmaceutically acceptable carrier or [to] diluent.

11. (Once Amended) A method of treating or preventing or reducing the susceptibility to *C. tetani* infection in human or animal, which comprises administering to the human or animal an effective amount of a polypeptide according to [any one of] claim[s] 1 [to 4, a polynucleotide according to claim 5 or a vector according to claim 6].

13. (Once Amended) A method for producing antibodies which recognise epitopes within a TeNT polypeptide, which method comprises administering a polypeptide according to [any one of] claim[s] 1 [to 4, a polynucleotide according to claim 5 or a vector according to claim 6] to a mammal.

14. (Once Amended) A method of treating *C. tetani* infection in a human or animal, which comprises administering to a human or animal an effective amount of an antibody produced according to claim [12 or] 13.